FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess dose related safety, early efficacy, pharmacokinetics
and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).